212 related articles for article (PubMed ID: 35656636)
1. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma.
Yamazaki N; Isei T; Kiyohara Y; Koga H; Kojima T; Takenouchi T; Yokota K; Namikawa K; Yi M; Keegan A; Fukushima S
Cancer Sci; 2022 Aug; 113(8):2798-2806. PubMed ID: 35656636
[TBL] [Abstract][Full Text] [Related]
2. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
3. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
[TBL] [Abstract][Full Text] [Related]
4. Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis.
Stahlie EHA; Mulder EEAP; Reijers S; Balduzzi S; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; Grunhagen DJ; van Akkooi ACJ
Crit Rev Oncol Hematol; 2022 Jul; 175():103705. PubMed ID: 35569723
[TBL] [Abstract][Full Text] [Related]
5. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Chesney J; Awasthi S; Curti B; Hutchins L; Linette G; Triozzi P; Tan MCB; Brown RE; Nemunaitis J; Whitman E; Windham C; Lutzky J; Downey GF; Batty N; Amatruda T
Melanoma Res; 2018 Feb; 28(1):44-51. PubMed ID: 29176501
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM
EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575
[TBL] [Abstract][Full Text] [Related]
7. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL
J Clin Oncol; 2018 Jun; 36(17):1658-1667. PubMed ID: 28981385
[TBL] [Abstract][Full Text] [Related]
8. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
Puzanov I; Milhem MM; Minor D; Hamid O; Li A; Chen L; Chastain M; Gorski KS; Anderson A; Chou J; Kaufman HL; Andtbacka RH
J Clin Oncol; 2016 Aug; 34(22):2619-26. PubMed ID: 27298410
[TBL] [Abstract][Full Text] [Related]
9. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
[TBL] [Abstract][Full Text] [Related]
10. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Chesney JA; Ribas A; Long GV; Kirkwood JM; Dummer R; Puzanov I; Hoeller C; Gajewski TF; Gutzmer R; Rutkowski P; Demidov L; Arenberger P; Shin SJ; Ferrucci PF; Haydon A; Hyngstrom J; van Thienen JV; Haferkamp S; Guilera JM; Rapoport BL; VanderWalde A; Diede SJ; Anderson JR; Treichel S; Chan EL; Bhatta S; Gansert J; Hodi FS; Gogas H
J Clin Oncol; 2023 Jan; 41(3):528-540. PubMed ID: 35998300
[TBL] [Abstract][Full Text] [Related]
11. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
[TBL] [Abstract][Full Text] [Related]
12. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries.
van Akkooi ACJ; Haferkamp S; Papa S; Franke V; Pinter A; Weishaupt C; Huber MA; Loquai C; Richtig E; Gokani P; Öhrling K; Louie KS; Mohr P
Adv Ther; 2021 Feb; 38(2):1245-1262. PubMed ID: 33368016
[TBL] [Abstract][Full Text] [Related]
14. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
Chesney JA; Puzanov I; Collichio FA; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan T; Hauschild A; Lebbé C; Joshi H; Snyder W; Mehnert JM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142291
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
Rohaan MW; Stahlie EHA; Franke V; Zijlker LP; Wilgenhof S; van der Noort V; van Akkooi ACJ; Haanen JBAG
BMC Cancer; 2022 Aug; 22(1):851. PubMed ID: 35927710
[TBL] [Abstract][Full Text] [Related]
16. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL
J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039
[TBL] [Abstract][Full Text] [Related]
17. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.
Stahlie EHA; Franke V; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ
Cancer Immunol Immunother; 2021 Aug; 70(8):2291-2300. PubMed ID: 33507342
[TBL] [Abstract][Full Text] [Related]
18. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.
Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE
J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
Burke EE; Zager JS
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
[TBL] [Abstract][Full Text] [Related]
20. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Corrigan PA; Beaulieu C; Patel RB; Lowe DK
Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
